RE:RE:RE:RE:RE:RE:RE:RE:RE:Impressive Roster of connectionsTo add to my post AP- at this moment no one is willing to stretch and pay 31 cents per share for this Late Stage P3 and multi FDA approvals- so yes I think a $5.00 offer from "them" to retail holders would in all likelihood be accepted.